Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Tiny roundworm points to big promise

By Drug Discovery Trends Editor | January 6, 2012

Two related studies from Northwestern University
offer new strategies for tackling the challenges of preventing and treating
diseases of protein folding.

To do its job properly within the cell, a protein first must
fold itself into the proper shape. If it doesn’t, trouble can result. More than
300 diseases have at their root proteins that misfold, aggregate, and
eventually cause cellular dysfunction and death.

The new Northwestern research identifies new genes and
pathways that prevent protein misfolding and toxic aggregation, keeping cells
healthy, and also identifies small molecules with therapeutic potential that
restore health to damaged cells, providing new targets for drug development.

The genetic screening study is published in PLoS Genetics.
The small molecule study is published in Nature Chemical Biology.

“These discoveries are exciting because we have
identified genes that keep us healthy and small molecules that keep us
healthy,” said Richard I. Morimoto, who led the research. “Future
research should explain how these two important areas interact.”

Morimoto is the Bill and Gayle Cook Professor of Biology in
the department of molecular biosciences and the Rice Institute for Biomedical
Research in Northwestern’s Weinberg College of Arts and Sciences. He also is a
scientific director of the Chicago Biomedical Consortium.

The genetic study reported in PLoS Genetics was
conducted in the transparent roundworm C. elegans, which shares much of
the same biology with humans. The small animal is a valued research tool
because of this and also because its genome, or complete genetic sequence, is known.

In the work, Morimoto and his team tested all of the
approximately 19,000 genes in C. elegans. They reduced expression of
each gene one at a time and looked to see if the gene suppressed protein
aggregation in the cell. Did the gene increase aggregation or lessen it or have
no effect at all?

The researchers found 150 genes that did have an effect.
They then conducted a series of tests and zeroed in on nine genes that made all
proteins in the cell healthier. (These genes had a positive effect on a number
of different proteins associated with different diseases.)

These nine genes define a core homeostastis network that protects
the animal’s proteome from protein damage. “These are the most important
genes,” Morimoto said. “Figuring out how nine genes—as opposed to 150—work
is a manageable task.”

In the Nature Chemical
Biology
study, Morimoto and his colleagues screened nearly one million
small molecules in human tissue culture cells to identify those that restore
the cell’s ability to protect itself from protein damage.

They identified seven classes of compounds (based on
chemical structure) that all enhance the cell’s ability to make more protective
molecular chaperones, which restore proper protein folding. The researchers
call these compounds proteostasis regulators. They found that the compounds
restored the health of the cell and resulted in reduction of protein
aggregation and protection against misfolding. Consequently, health was
restored when diseased animals were treated with the small molecules.

Morimoto and his team then conducted detailed molecular analyses
of 30 promising small molecules, representing all seven classes. They
discovered some compounds were much more effective than others.

“We don’t yet know the detailed mechanisms of these
small molecules, but we have identified some good drug targets for further
development,” Morimoto said.

Article Abstract

SOURCE – Northwestern University


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE